Last reviewed · How we verify
Recombinant Human Prourokinase
At a glance
| Generic name | Recombinant Human Prourokinase |
|---|---|
| Also known as | rhPro-UK |
| Sponsor | Tasly Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) (PHASE3)
- ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE) (PHASE3)
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PHASE3)
- A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (PHASE2)
- Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) (PHASE3)
- Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PHASE3)
- Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (PHASE4)
- Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |